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Abstract
Paediatric chordomas are rare malignant tumours arising from primitive notochordal remnants with a high rate of
recurrence. Only 5 % of them occur in the first two decades such less than 300 paediatric cases have been reported
so far in the literature. In children, the average age at diagnosis is 10 years with a male-to-female ratio closed to 1.
On the opposite to adults, the majority of paediatric chordomas are intracranial, characteristically centered on the
sphenooccipital synchondrosis. Metastatic spread seems to be the prerogative of the under 5-year-old children with
more frequent sacro-coccygeal locations and undifferentiated histology. The clinical presentation depends entirely
on the tumour location. The most common presenting symptoms are diplopia and signs of raised intracranial
pressure. Sacrococcygeal forms may present with an ulcerated subcutaneous mass, radicular pain, bladder and
bowel dysfunctions. Diagnosis is suspected on computerised tomography showing the bone destruction and with
typically lobulated appearance, hyperintense on T2-weighted magnetic resonance imaging. Today, treatment relies
on as complete surgical resection as possible (rarely achieved because of frequent invasiveness of functional
structures) followed by adjuvant radiotherapy by proton therapy. The role of chemotherapy has not been proven.
Prognosis is better than in adults and depends on the extent of surgical resection, age and histology subgroup.
Biological markers are still lacking to improve prognosis by developing targeted therapy.
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Résumé
Les chordomes pédiatriques sont des tumeurs rares développées à partir de résidus de la notochorde primitive et
qui présentent un haut taux de récidive locale. Les chordomes des sujets de moins de 20 ans représentent
seulement 5 % de l’ensemble de ces tumeurs, justifiant que moins de 300 cas de chordomes pédiatriques aient été
publiés dans la littérature à ce jour. Chez l’enfant, l’âge moyen au diagnostic est de 10 ans avec un ratio garçon-fille
proche de 1. Contrairement à l’adulte, la majorité des chordomes pédiatriques sont intra-crâniens, typiquement
localisés en regard de la synchondrose sphéno-occipitale. La dissémination métastatique semble être l’apanage
des enfants de moins de 5 ans, avec des localisations sacro-coccygiennes et une histologie indifférenciée plus
fréquentes. La présentation clinique dépend essentiellement de la localisation de la tumeur. Les symptômes les
plus fréquemment retrouvés au diagnostic sont la diplopie et les signes d’hypertension intra-crânienne. Les formes
sacro-coccygiennes peuvent se présenter sous la forme d’une masse sous-cutanée ulcérée, ou bien par des douleurs
radiculaires ou des troubles vésico-sphinctériens. Le diagnostic est suspecté devant une lésion ostéolytique au scanner,
classiquement lobulée et en hypersignal T2 en IRM. Aujourd’hui, le traitement repose sur une résection chirurgicale
aussi complète que possible (rarement obtenue du fait de l’envahissement fréquent de structures fonctionnelles par
ces tumeurs), suivie d’une radiothérapie adjuvante aux protons. Le rôle de la chimiothérapie n’a pas été démontré. Le
pronostic est meilleur chez l’enfant que chez l’adulte, et il dépend de la qualité de la résection chirurgicale, de l’âge et
du type histologique. A ce jour, aucun marqueur n’a pu être mis en évidence, qui permettrait de développer des
thérapies ciblées et améliorer le pronostic de ces tumeurs.
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Introduction
Paediatric chordomas are rare malignant tumours which
involve the cranial base and spinal column. They seem
to be different from their adult’s counterparts. The aim
of this article is to give an update review of clinical and
histopathological features, diagnostic criteria, genetic
markers, prognosis factors and current treatment. Data
discussed in this review were obtained from a Pubmed






Chordomas are rare tumours arising from primitive noto-
chordal remnants [1]. Their anatomopathological classifi-
cation is the same for adults and children and distinguishes
“classic” (“chordoma NOS” Not Otherwise Specified),
“chondroid” and “undifferentiated” chordomas.
Luschka first described the existence of small soft trans-
parent “jelly-like” tumours of the clivus blumenbachii
(dorsum sellae) in 1857 [2], and Ribbert introduced the
term “chordoma” thirty years later [3]. While one of the
first cases of chordoma was described by Klebs in 1864,
the first paediatric cases were reported many years later
by André-Thomas [4] and Adson [5] in 1923 and 1935.
The diagnosis of a patient with a chordoma is based
on clinical, topographical and radiological (multilobu-
lated, hyperintensity in T2 weighted sequences) findings,
and is then confirmed by characteristic histological find-
ings. Chordomas are characterized by their aggressive
potential and their frequency of recurrence. Manage-
ment of these tumours is based on as complete as pos-
sible primary resection followed by local irradiation,
ideally proton beam therapy.
Epidemiology
Chordomas comprise 0.2 % of primary brain tumours [6, 7]
and less than 5 % of primary bone tumours [6, 8, 9]. They
occur in less than 1/1,000,000 population [8, 10], with a
peak incidence occurring between the fourth and sixth de-
cades [11–13]. Less than 5 % of chordomas present in the
first two decades [11, 14–16].
Among children, the average age at diagnosis was
around 10 years [15–20], and the youngest case de-
scribed was in a neonate with a tumour of the clivus
[21]. In contrast to adults [6, 12, 22], sacro-coccygeal
chordomas in children occur at a younger age than
those in the cranium. For all localisations, the male to
female ratio is close to 1 [15, 18].
Clinical description
Anatomical localisation
In the literature, childhood chordomas are clearly distin-
guished from their adult’s counterparts by their anatom-
ical distribution. Adult chordomas are primarily found
in the sacro-coccygeal region [13, 15, 23–25], whereas
the majority of paediatric chordomas are intracranial (up
to 54 %) [15], characteristically centered on the sphe-
nooccipital synchondrosis [11, 15, 17, 26, 27]. Local de-
struction of the clivus with extradural compression of
the neuroaxis is a characteristic feature. Other locations
are anecdotic (gluteal region [28], paranasal sinuses [29],
ethmoid and maxillary sinuses [30], temporal bone [31]).
Cases of intradural lesions [32–34] and chordomas aris-
ing in the paravertebral or paraclival regions without as-
sociated bony invasion have also rarely been reported
[35, 36].
Intracranial chordomas
Impairment of cranial nerve function is the principle
presenting feature of chordomas of the cranial base in
approximately 60 % of cases [19, 23], the sixth nerve be-
ing the most frequently involved (55 to 72 % of cases)
[16]. Headaches occur in around 40 % of cases [16, 23],
due to increased intracranial pressure (ICP) in 28 % of
cases [23]. Long tract signs with a pyramidal syndrome
may occur in 36 % of cases [23].
Children less than 5 years present frequently with in-
creased ICP (72 %), long tract signs (43 %) and also
lower cranial nerves palsy and torticollis probably due to
a more frequent inferior extension of lesions at this age
[24]. Older children will present with diplopia or isolated
headaches (55 % et 42 % respectively) [21, 23, 24].
Sacro-coccygeal chordomas
These present with the rapid appearance of an eventu-
ally ulcerated subcutaneous mass [37–39] occasionally
massive within the presacral space. Perineal pain, radicu-
lar pain [39, 40] or cauda equina syndrome may occur
[39, 40]. Bladder and bowel dysfunction is common
through compression and/or invasion of the nerves of
the cauda equina or by direct compression of the urinary
tract and colon by the presacral mass [37, 41].
Vertebral column chordomas
The predominant symptoms depend on the orientation
and development of the tumour. In the majority of cases,
posterior enlargement of the tumour causes compression
of the spinal cord or cauda equina [17, 26, 42–45]. An-
terior progression can present with respiratory dysfunc-
tion and/or dysphagia in those tumours of the cervical
and thoracic regions [46]. Pain is common and rigidity
and/or spinal deformity have been similarly reported
[17, 43, 47, 48].
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Metastatic dissemination
The incidence of chordoma metastases is quite variable,
from 8.6 to 58 % in children [15, 17–19]. There appears
to be a link between their incidence and local recurrence
[19, 49]. Metastatic spread seems to be the prerogative
of the under 5-year-olds [16, 23, 50], and essentially con-
cerns tumours of the sacro-coccygeal region or of the
spinal column. Metastatic dissemination primarily oc-
curs via the blood circulation, but also via the cerebro-
spinal fluid, either via the subarachnoid spaces [50, 51]
or through ventricular shunting [52]. There is also the
risk of metastatic tumour deposition through the surgi-
cal route [53]. The principle site of metastases is the lungs
[15–17, 34, 51, 54–57], followed by bone [50, 57], lymph
nodes (cervical, inguinal, sub-clavicular) [15, 17, 57, 58],
skin [50, 59], liver [19, 50, 59] and anecdotally the brain
and spinal cord [59], meninges [50, 51], heart [59], pleura
[15], kidney [59] and suprarenal glands [17, 23].
Aetiology
Embryology
The term “notochorde” comes from the ancient greek
noton (back) and chorde (cord), literally “dorsal cord”. It
is a dorsal tubular structure occurring in embryos of all
chordates [60]. In vertebrates, the notochord is replaced
during development by the vertebral column and part of
the cranial base. It has long been considered that the nu-
cleus pulposus was the point of origin of chordomas.
However, the origin of chordomas from the vertebral
bodies, their main localisations at the extremities of the
cranio-vertebral axis [13, 15, 23] and the absence of bra-
chyury (a specific marker of chordomas) in the interver-
tebral discs [61] place into doubt the link between
chordomas and the nucleus pulposus.
The fact that chordomas arise from notochordal cells
is supported by different arguments. Apart from their
identical location, there exists morphological and immu-
nophenotypical similarities between the cells of chordo-
mas and those of the notochord [62].
In fact, chordomas arise from notochordal remnants
from an incomplete involution of the notochord and dif-
ferent from “normal” remnants potentially found in the
nuclei pulposi.
Molecular biology
Publications on this subject are infrequent and not spe-
cific to childhood chordomas. The majority of chordo-
mas demonstrate hypodiploidy or pseudodiploidy with
numerous structural rearrangements. Chromosomal de-
letions are more frequent than gains. The more frequent
cytogenetic anomalies are monosomy 1 and a gain on
chromosome 7 [63].
The brachyury growth factor (growth factor T) is a spe-
cific marker of chordomas, implicated in notochordal de-
velopment. Its locus 6q27 is frequently amplified within
chordoma cells and its inactivation can block growth of
chordoma tumour cell lines (U-CH1) in vitro [64].
Numerous tyrosine kinase receptors are richly expressed
in chordoma cells, such as EGFR (epithelial growth factor)
[65], α and β PDGFR (platelet-derived growth factor), c-
KIT [66, 67] and IGF-1 receptor [68]. Tumour suppressor
genes CDKN2A, CDKN2B [17, 69] and FHIT [69] may
also be implicated in the oncogenesis of chordomas.
Mutation of tumour suppressor genes TSC1 et TSC2
is seen in patients with chordomas associated with Tu-
berous Sclerosis. This association is specific to the paedi-
atric population. Chordomas in these patients occur in
very young children, are frequently sacral with a better
long term prognosis [70]. The genes TSC1 and TSC2,
being of the mTOR pathway, have raised the possibility
that this pathway is implicated in intracellular signalling
for oncogenesis in chordomas.
Diagnostic methods
Computerised tomography (CT) [71]
CT is essential for evaluating bony integrity and bone
destruction of the skull base and also potential vertebral
instability induced by tumour invasion (Fig. 1). In brain
Fig. 1 CT scanner of a clival chordoma. a. Axial brain window. The retroclival lesion developed posteriorly (dotted line) with contact to the
brainstem (arrowhead). b. Axial bone window. Erosion of both posterior clinoid proccesses by the chordoma (arrows). c. Erosion of the posterior
side f the clivus (arrow)
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windows chordomas often appear heterogeneous due to
the interspersing of tumour tissue (isodense), with areas
of necrosis or myxoid cysts (hypodense). The hyperden-
sity frequently observed corresponds to bony sequestra-
tion from destruction of cortical and cancellous bone
rather than tumoural calcification.
Magnetic Resonance Imaging (MRI)
MRI provides accurate evaluation of the involvement of the
adjacent soft tissues, including vasculature, cranial nerves,
and changes in the brainstem related to tumour itself.
Chordomas are iso/hypointense on T1-weighted images,
with hyperintensity due to haemorrhage or cyst formation.
The lesion is typically hyperintense on T2-weighted images,
with a lobulated appearance and multiple hypointense sep-
tae (Fig. 2). The majority of intracranial chordomas demon-
strate moderate to marked heterogeneous enhancement
following contrast. If present, it is often heterogeneous,
with a “honeycomb” appearance of the septae, whilst areas
of necrosis or mucoid containing remain iso/hypointense.
Angiography
Angiography is rarely useful but may provide additional
informations to determine the relationship of the chor-
doma to vascular structures when equivoque on MR
angiography. Exceptional temporary occlusion may be
performed to determine the potential risk of vascular
sacrifice during surgical procedures.
Pathology
Macroscopically chordomas are blue or slate grey tumours,
frequently soft and gelatinous. They are encapsulated
nodular tumours that may contain areas of haemorrhage,
necrosis or even cysts.
Chordomas have been divided into three histopatho-
logic subtypes: typical or conventional chordomas, chon-
droid chordomas and dedifferentiated chordomas [1].
Microscopically, they have a characteristic architecture
comprising of cells arranged in sheets or in lobules sur-
rounded by an abundant myxoid extracellular matrix.
Some tumour cells are quite large with numerous intra-
cytoplasmic mucine or glycogen rich vacuoles: these are
the characteristic physaliferous cells. Notably, approxi-
mately 10 % of chordomas do not contain physaliferous
cells; the frequency of these cells can vary from 1 to
100 %. Generally, chordomas demonstrate a high degree
of intratumoural heterogeneity [1]. Foci of intratumoural
necrosis are frequent and often extensive. Mitoses, nu-
clear atypia and pleomorphisms are present to a variable
degree.
Chondroid chordomas present an extracellular matrix
that resembles those of hyaline cartilaginous tumours
[1]. The distribution of the different histological entities
can vary from simple chondroid foci dispersed within a
predominantly chordoid structure to an equal distribution
of the chondroid and chordoid components [13, 72].
Undifferentiated chordomas are mixed tumours pre-
senting features of classic chordomas in association with
foci of osteosarcoma or of high grade undifferentiated
malignant spindle cell tumours [1].
Conventional and chondroid chordomas express epi-
thelial markers including cytokeratins (notably CK 8, 18
and 19), Epithelial Membrane Antigen (EMA), S-100
protein, and specifically brachyury. On the contrary,
undifferentiated chordomas lack reactivity for these
Fig. 2 T2 weighted MRI of a clival chordoma. a. Axial plane. A voluminous chordoma developed from the clivus with extension to both
cerebellopontine angles (single arrowheads). Brainstem is pushed back posteriorly (double arrowhead). b. Sagittal plane. The chordoma eroded
the inferior part of the clivus (asterisk) and developed anteriorly to the cervical spine. Typical lobulated appearance with multiples hypointense
septae can be observed
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epithelial markers. Yadav et al. observed that paediat-
ric chordomas more frequently show p53 expression
and loss of INI1, and have higher MIB-1 labelling
index compared to their adult’s counterparts [73].
The distinction between these diverse chordoma
tumour entities is not yet fully elucidated. Immunohisto-
chemistry and molecular biological markers will prob-
ably contribute to classify these tumour variants.
Differential diagnosis
Benign notochordal cell tumour. These entities
could be benign forms of chordoma [74]. Differential
diagnosis is made on clinical and histological
criterions [75].
Chondrosarcomas. Tumours of the median axis,
chondrosarcomas have more likely linear or globular
calcifications and do not express epithelial markers nor
brachyury [76].
Chordoid meningiomas. A differential diagnosis of
intradural chordomas.
Genetic counselling
There is currently no particular genetic counseling as
only few familial chordoma cases have been reported
with different genetic abnormalities [77–86]. Variable
losses of 1p [82, 83], 7q LOH [86] and a unique duplica-
tion of a region on 6q27 containing only the T gene
(brachyury) [85] have been described.
Management including treatment
Management of chordomas is multidisciplinary and be-
cause of the rarity of this disease, should ideally be per-
formed in a specialized centre. Due to the high risk of
relapse, management of this disease must be aggressive.
The advent of MRI, the advances in neurosurgery (en-
doscopy) and the contribution of proton beam therapy
have allowed considerable prolongation of life for these
patients. Indeed, when comparing the survival rates of
children treated before and after 1990 in the literature,
there is a statistically significant difference in overall sur-
vival with the more recent cases having a better outcome
(p = 0,001, log rank; data available for 153 cases from a
review of 249 cases of intracranial and spinal chordo-
mas). Today, treatment relies on as complete as possible
surgical resection followed by adjuvant radiotherapy by
proton therapy. Standard chemotherapy has no role even
if certain authors have utilized chemotherapy with occa-
sionally encouraging results.
Surgery
Surgery is the first and essential step in the treatment of
chordomas. The objectives are twofold: (1) maximal reduc-
tion in tumour volume with obtaining a macroscopically
complete excision and (2) to remove any possible tumour
residual away from neurovascular structures (spinal cord,
brainstem, large vessels, internal auditory meatus, optic
pathways and hypophysis) to maximize radiotherapy dose
whilst minimizing secondary effects.
As in adults, all authors agree that the largest surgical
resection possible must be achieved at the initial surgery
[11, 13, 19, 87–90]. This attitude is commonly accepted,
even if the paediatric series in the literature are too little
to allow a real statistical analysis. Ridenour observed a
better survival following a complete excision versus an
incomplete excision in 35 children, without achieving
statistical significance [18]. The localization of these tu-
mours and the complexity of their extension allows a
complete resection in the minority of cases [7, 91] due
to the proximity to neural structures (cranial nerves,
brainstem, sacral nerves) or vascular structures. The rate
of complete surgical excision remains low in the major
paediatric series published and varies between 0 % to
36.4 % [11, 17–19]. Maximal tumour resection often re-
quires many surgical attempts [92], in utilizing different
surgical routes in one or more procedures. The majority
of routes to the cranial base currently used in adults
may be applied to children with little modification and
are well tolerated [93].
Orthopaedic management may be necessary in order
to prevent or treat instability when spine is involved
[27, 45, 46, 48, 94].
Radiotherapy
Although radiotherapy is currently an integral part of
the treatment of adult chordomas, issues regarding both
the timing and optimal type of radiotherapy are largely
unresolved in the literature [95]. Besides, very few data
are available concerning the paediatric population and
no comparative study has proven the benefit of radio-
therapy following surgical resection in the outcome of
paediatric chordomas.
The series published by Wold et al. is the only one that
assessed the impact of conventional radiotherapy in paedi-
atric chordomas [11]. Twelve patients (mean age 13.6 years)
were treated for intracranial chordomas with a total or
partial resection, followed in ten cases by conventional
radiotherapy. After a mean follow-up of 67 months, two
patients had died from disease, and the overall survival
reached 75 % at 5 years. All patients alive at last follow-up
had benefited from the association of surgery and radio-
therapy. In a more general point of view, Borba et al., in a
review of intracranial chordomas, confirmed that surgical
excision, whether complete or incomplete, followed by
radiotherapy (type not precise), offered a better outcome
than surgical excision alone (p = 0.004, outcome of each
group not precise) [16]. Actually, the majority of authors
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have recommended adjuvant radiotherapy [6, 42, 96, 97]
after as complete as possible tumour resection.
The necessity of high dose radiotherapy in the treat-
ment of chordomas [98], and the numerous potential
complications of radiotherapy in growing children (pitu-
itary deficiency, cognitive and neurosensory impairment,
brain radionecrosis, necrosing leucoencephalopathy, fer-
tility disorder, growing disorders) [99] lead to consider
proton therapy as a radiotherapy modality of choice for
paediatric chordomas, as it reduces by a factor of 2–3
the dose delivered to neighbouring structures [100].
Overall survival rates from 60 to 89 % after 5 to
7.25 years have been observed after treatment of cra-
nial base and cervical chordomas by surgical removal
followed by proton therapy (eventually associated with
conventional radiotherapy) [19, 20, 101–103]. Side ef-
fects described in the different series published seem
to be limited compared to conventional therapy. They
are essentially represented by hypopituitarism, hypoa-
cousy or worsening of anterior visual deficit; temporal
lobe necrosis, cerebellar and brainstem parenchymal dam-
age have also been punctually reported [19, 101–104].
Proton beam therapy may be used in young children,
eventually under general anaesthesia [105]. It has been
reported proton irradiation of skull base tumours in pa-
tients less than one year of age [106]. Although good
outcomes have been reported in the series of patients
treated with proton therapy, no study directly com-
pared the results of this radiotherapy modality to those
of conventional therapy.
Chemotherapy
Similarly to adults, utilisation of chemotherapy in the
management of paediatric chordomas is anecdotal
with only 20 or so cases reported in the literature
[11, 17, 19, 58, 59, 80, 107–109]. Some authors con-
sider that chemotherapy used for sarcomas can also
be used in undifferentiated chordomas [59, 110], such
as ifosfamide and etoposide [58, 107] or doxorubicine
[107, 109]. Whatever the agent used, chemotherapy has
been used after relapse or in some metastatic cases with
disappointing results. One publication reports a brief case
of a 7-month old infant treated for a clival chordoma who
had a durable complete response with chemotherapy
alone (including vincristine, doxorubicin, cyclophospha-
mide, ifosfamide, etoposide and carboplatin) [111], but no
data exist on the potential benefit of chemotherapy before
any surgery.
Based on recent studies in molecular biology, the ten-
dency in oncology has become to use targeted therapies
as adjuvant treatment. Unfortunately, only few adult
series have been available so far in the field of chordo-
mas. Symptomatic and radiological improvement has
been observed in adult treated by Gleevec® (Imatinib,
tyrosine kinase inhibitor). This molecule has also been
infrequently used in children without encouraging result
[67, 112, 113]. Inhibitors of the mTOR pathway (siroli-
mus) and inhibitors of EGFR (cetuximab/gefitinib) have
also been used in cases of resistant chordomas [112] or
metastatic chordoma of the sacrum [114]. These obser-
vations need to be confirmed through large cohort stud-
ies with sufficient follow up and would require genomic
analyses of paediatric chordomas, which are probably
different compared to their adult’s counterparts.
Prognosis
Globally survival is better in children than in adults ex-
cept for the aggressive form of chordomas occurring in
children under 5 years of age. The overall survival rate
in the major paediatric series in the literature varies be-
tween 56.8 to 81 % [16, 18–20] (Table 1). These results
observed in the paediatric population are generally bet-
ter than those seen in adults where the survival rate
varies from 23 to 66 % [115, 116].
Histological subtype is probably the main prognostic
factor. Atypical and undifferentiated forms have clearly a
worst outcome, compared to classic and chondroïd
chordomas. Mortality rates for atypical (undifferenti-
ated/poorly differentiated) forms vary from 67 to 83 %,
compared to 14 to 27 % mortality rates for classic and
chondroïd forms [18, 20].
The localisation of the tumour may also influence the
prognostic. Intracranial lesions are considered to have a
better outcome than those in the spinal column, which
have a better outcome than those in the sacro-coccygeal
region [18, 19, 117].
Finally, a major prognostic factor identified in chordo-
mas was age of onset and it is notable that the worst
progression occurs in very young children, under the age
of 5 years [16, 17, 23, 50, 102, 118] ; the review of intra-
cranial chordomas by Borba is quite clear on this subject
[16]. Apart from a few cases, the majority of children less
than 5 years reported in the literature died within
18 months following diagnosis despite surgery, radio-
therapy and/or chemotherapy [15, 23–25, 50, 53, 58,
109, 117]. Age, where children under 5 years are more
prone to develop more aggressive tumours, however, is
not the only factor associated with a poorer outcome. It
may be explained by the frequency of sacro-coccygeal
localisations and atypical forms, and a more frequent
metastatic dissemination.
Unresolved questions
As for their adult’s counterparts, it is now largely ad-
mitted that surgery is the first step of the treatment of
paediatric chordomas, and that as complete as possible
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removal has to be reached in order to improve the out-
come. Interrogations still persist on the necessity of ad-
juvant therapy and its modality. Indeed, the usefulness
of radiotherapy after total resection of paediatric chor-
doma is still not established and would deserve pro-
spective analyses in international trials. One may ask if
radiotherapy is compulsory after complete resection of
a classical chordoma without invasion of functional
structures. Moreover, data from the molecular biology
will probably help us to distinguish in the future chor-
domas with a better prognosis that could be eligible to
a surgical treatment alone. Although proton therapy
has shown good outcomes in different studies, its su-
periority to other radiotherapy modalities has also to be
proven. On the contrary, chemotherapy has shown dis-
appointing results. Recent studies on biomolecular and
genetic analyses of chordomas lead to the identification
of promising targetable pathways. Use of such new tar-
geted therapies has shown encouraging results in adults
in case of advanced disease, but few paediatric patients
have been included in these studies. Complementary
studies will be necessary in order to assess their role in the
treatment of paediatric chordoma, either as neoadjuvant
treatment, or in case of progressive disease after standard
treatments.
Conclusions
Paediatric chordomas are rare malignant tumours with a
high rate of recurrence. While prognosis is better than
in adults, patients less than 5 years of age generally
present with very aggressive disease and poor outcome.
The surgical removal of the tumour still is the first step
of the treatment and has to be as complete as possible.
As for adults, proton beam therapy is the adjuvant treat-
ment of reference, even if its benefit in some cases may
be discussed. The role of chemotherapy has not been
proven, but advances in genetics and molecular biology
may help to develop targeted therapies during the next
decades.
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survival (%)Surgery Radiotherapy Chemotherapy
Benk et al.[19] 18 Partial resection
(18)
Proton (18) - 72 (19–120) 63 (5 years) 68
(5 years)
Borba et al.[16] 79
(review)
Not precise Not precise Not precise 39 (1–300) - 56.8
Hoch et al.[20] 73 Total/Partial
resection (73)
Proton (73) - 90 (12–252) - 81
Ridenour et al.[18] 20 Partial (14) Conventional (10) (2) 129 (1–501) - 63
Proton (2)
None (2)
Total (4) Conventional (2)
None (2)
Biopsy (2) Conventional (2)
Necker - Lariboisière
(not published)








Total (6) Conventional (2) Proton (3)
Conventional + Proton (1)
(1)
Unknown (4)
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